Torbay Pharmaceuticals, Ltd. – FDA 483, Nov 12, 2024

An FDA inspection conducted at Torbay Pharmaceuticals, Ltd. in Paignton, Devon, United Kingdom, from November 4-12, 2024, revealed significant deviations from Good Manufacturing Practice (GMP) regulations. The observations, detailed in a Form FDA 483, highlight several critical areas requiring immediate attention.

Firstly, the company failed to thoroughly investigate unexplained discrepancies, specifically the consistent presence of particles in multiple batches of an injectable drug product. Despite numerous rejected vials, no root cause investigation was initiated, raising concerns about product quality and safety.

Secondly, the quality control unit demonstrated a lack of adequate oversight. Investigators found uncontrolled, discarded GMP-related documents, including laboratory printouts and batch records, suggesting insufficient data integrity practices. Additionally, Torbay Pharmaceuticals failed to provide a comprehensive Piping and Instrumentation Diagram for its critical water system, essential for manufacturing sterile and non-sterile products.

Thirdly, equipment cleaning and maintenance were found to be deficient. Rust-like discoloration was observed within the aseptic filling zone of a critical production line, posing a contamination risk. The design of this same filling line necessitated frequent, unplanned operator interventions in the aseptic area due to fluid accumulation. Furthermore, a recovery study for cleaning validation was deemed inadequate.

Finally, deficiencies were noted in the monitoring system for aseptic processing environmental conditions, including an inadequate cleaning validation recovery study for non-dedicated equipment and an insufficient airflow pattern study.

Torbay Pharmaceuticals, Ltd. is required to provide a robust response detailing corrective actions to address these serious observations to ensure compliance with regulatory standards and safeguard product quality.